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Objective(s): One of the common heterogeneous reproductive disorders in women of childbearing 
age is polycystic ovary syndrome (PCOS). It is characterized by lack of fertility due to anovulatory 
cycles, hyperandrogenemia, polycystic ovaries, hyperinsulinemia, and obesity. Both reproductive 
anomalies and metabolic disorders are involved in PCOS pathology. Although the role of increased 
levels of androgens in initiation of PCOS is almost proven, mechanisms of PCOS pathophysiology are 
not clear. Here we discuss roles of altered metabolic conditions, obesity, and chronic inflammation in 
PCOS pathophysiology.
Materials and Methods: : In this review, we attempted to identify genes related to obesity and chronic 
inflammation aspects of PCOS and their physiological functions to explain the pathways that are regulated 
by these genes and can be a prominent function in PCOS predisposition. For this purpose, published articles 
and reviews dealing with genetic evaluation of PCOS in women in peer-reviewed journals in PubMed and 
Google Scholar databases were included in this review.
Results: Obesity and chronic inflammation are not prominent diagnostic features of PCOS, but they 
play an important role in exacerbating metabolic and hyperandrogenic states. ADIPOQ, FTO TGFβ, 
and DENND1A as the main obesity- and chronic inflammation-related genes have roles in PCOS 
pathophysiology.
Conclusion: It seems that genes related to obesity pathology in genomic research association, are 
related to metabolic aspects and body mass index in PCOS patients. Genomes have roles in chronic 
inflammation, followed by obesity, in the pathogenesis of PCOS.
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Introduction
Polycystic ovary syndrome (PCOS), affects 5–15% 
of reproductive-aged women in the world. It is one of 
the most prevalent endocrine abnormalities that are 
characterized by biochemical hyperandrogenemia, 
chronic anovulation, and polycystic ovaries (1). Besides, 
PCOS relates to other symptoms among which insulin 
resistance, abdominal obesity, chronic inflammation, 
elevated risk of metabolic syndrome, type 2 diabetes, 
and cardiovascular diseases are more pronounced 
(1). The genetic basis of PCOS by twin-family based 
association studies was confirmed, and accordingly, 
heritability of PCOS is estimated 70% (2). The 
genome-wide association studies (GWAS) identified 15 
susceptible single nucleotide polymorphisms (SNP) in 
11 loci (LHCGR, FSHR, THADA, INSR, DENND1A, RAB5B, 
C9orf3, YAP1, SUMO1P1, TOX3, and HMGA2) in PCOS 
Chinese women (3, 4). These loci (LHCGR, FSHR, INSR, 
THADA, DENND1A, and YAP1) are likely more important 
because they were replicated in European population, 
too (5-8). Undoubtedly, effects of environmental factors 
in interacting with genetic agents in creating important 
features, such as hyperandrogenism and insulin 
resistance of PCOS cannot be ignored (9). 
The lifestyle interacts with genetics in the incidence 
of weight excess and obesity. For instance, sisters 
with irregular menses and hyperandrogenism were 
overweight in contrast with ones who have regular 
cycles and hyperandrogenism. Abdominal adiposity, 
excess weight, and obesity are usually common 
among PCOS patients. Obesity plays an underscored 
role in pathophysiology of insulin resistance and 
hyperandrogenism (10). For this reason, diet 
modification and exercise play an important role in 
improving PCOS reproductive and metabolic phenotypes 
(11, 12). 
PCOS is also related to elevation of inflammatory 
indices such as increased levels of c- reactive protein, 
interleukins, and white blood cell count as well as 
oxidative stress and endothelial dysfunction, which are 
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components of low-grade chronic inflammation (13). 
Adipose tissue products can play a role in inflammation 
creation and its exacerbation. Interleukin 6 (IL-6) 
secreted from adipocytes, stimulates secretion of 
hepatic C-reactive protein (CRP) and both of them 
elevate in PCOS and obese patients (14). Abdominal 
obesity is associated with dysregulation of sex steroid 
levels in PCOS, such as androgen overproduction and 
reduction of sex hormone-binding globulin (SHBG). The 
problem is that obesity has a confounding effect on the 
exacerbating of PCOS main traits, hyperandrogenism, 
and insulin resistance (15). 
Obesity influences the development or escalation of 
PCOS. Mother’s obesity in late pregnancy predisposes 
her daughter to PCOS in adulthood, but effective 
pathophysiologic mechanisms are not clear (16). Also, 
the intrauterine androgen excess may create adiposity 
in offspring at adulthood. Abdominal obesity can be 
important in ovarian or adrenal hyperandrogenism 
in PCOS, although, the elevated levels of androgens 
can contribute to abdominal fat deposition (10). 
Apart from the key role of hyperandrogenism in PCOS 
pathophysiology, obesity, inflammation, and other 
metabolic factors have the main role in aggravating 
steroidogenic abnormalities. Furthermore, genetic 
predisposition underlies both primary steroidogenic 
disorders and other exacerbating factors (10). Obesity 
is related to low-grade chronic inflammation, which 
contributes to insulin resistance by adipocytokines 
functions such as tumor necrosis factor alpha (TNFα) 
and adiponectin (17, 18). 
In this review, we attempted to identify genes 
related to obesity and chronic inflammation aspects of 
PCOS and their physiological functions to explain the 
pathways that are regulated by these genes and can be 
a prominent function in PCOS predisposition. Initially, 
we searched the major databases such as PubMed 
and Google Scholar based on gene, PCOS, obesity, 
inflammation, etiology, patient, and human keywords 
which were taken from the MeSH site. These genes are 
divided into two groups that are effective in obesity 
and chronic inflammation, respectively. Then, they are 
separated from each gene, their actions are described, 
and thus the involved physiologic pathways identified. 
Eventually, hypotheses associated with these findings 
are presented.
Even though the role of increased levels of androgens 
in the initiation of PCOS is almost documented and 
approved by most authors, mechanisms of PCOS 
pathophysiology are not clear. In fact, hyperandrogenism 
is the common loop of different hypotheses presented 
on PCOS etiology. These issues are explained in detail 
in a previous paper about the role of steroid and 
gonadotropin related genes in PCOS pathophysiology 
(19). But roles of altered metabolic conditions are 
prominent.
Obesity-related genes in etiology of polycystic ovary 
syndrome
Since the genetic nature of obesity is well known 
(20), environmental factors such as lifestyle, nutrition, 
and exercise also contribute to obesity. Obesity leads 
to insulin resistance, followed by other events that 
ultimately result in the occurrence of PCOS. Obesity can 
result from the reduced lipolytic effect of insulin in PCOS, 
in turn, by increased serum inflammatory mediators 
such as TNFα and high-sensitivity CRP (hs-CRP), leads 
to beta cell dysfunction and insulin resistance of PCOS. 
Obesity can intensify the hyperandrogenic state in 
PCOS because abdominal obesity alters fat-soluble 
androgen clearance and deposition and also exacerbates 
hyperandrogenism by reduction of SHBG levels.
Obesity is associated with PCOS, and between 38–88% 
of PCOS patients are overweight or obese (21). Obesity 
is accompanied by other PCOS metabolic attributes, 
such as insulin resistance (22). Obesity is related to 
insulin resistance and compensatory hyperinsulinemia 
(23). Central adiposity and hyperandrogenemia by 
reduction of natural insulin sensitizer adipokines 
such as adiponectin lead to the development of insulin 
resistance in PCOS (24). Also, both obesity and insulin 
resistance elevate the risk of cardiovascular and type 2 
diabetes mellitus diseases (25), which are considered 
metabolic features of PCOS. Body mass index (BMI) 
of women with PCOS is usually higher than normal 
women (26). Several growth factors and inflammatory 
factors were increased in obesity and could promote 
ovarian androgen overproduction (23). Thus, obesity 
can develop insulin resistance, androgen excess, and 
inflammation in PCOS women.
Dyslipidemia is prevalent in almost 70% of women 
with PCOS (27). In addition to obesity, dyslipidemia 
causes insulin resistance; in contrast, insulin resistance 
also affects lipid metabolism and serum lipid 
parameters, all of which are characteristics of PCOS 
(28). Dyslipidemia and metabolic syndrome have a 
pivotal role in PCOS development but not obesity and 
insulin resistance (25).
It seems that factors of genetic and lifestyle, both or 
alone lead to obesity in humans. Moreover, obesity has 
adverse effects on the physiological pathways in the body, 
which eventually result in PCOS metabolic parameters 
(Figure 1). Obesity is related to anovulation, loss of 
pregnancy, and occurrence of pregnancy complications 
(pre-eclampsia and gestational diabetes); as well as, 
delayed or failed responses to therapeutic strategies 
such as clomiphene citrate and gonadotropins. A five 
percent weight loss in women increased the rate of 
normal and spontaneous ovulation and pregnancy (25). 
Thus it seems the alteration of environmental factors 
such as exercise and diet is useful in the treatment of 
PCOS. But the effects of obesity-related genetic variants 
cannot be forgotten. Below, a number of these genes are 
described and are summarized in Table 1.
ADIPOQ
It is well known that insulin resistance is a prominent 
risk factor for obesity. The adipocyte cells are one of the 
target cells of insulin and secrete several adipokines 
such as adiponectin (34). About six polymorphisms 
of the adiponectin gene have been detected in various 
racial populations and with different environmental 
factors associated with metabolic abnormalities of PCOS. 
Among them, SNPs +45(T/G) and +276(G/T) are highly 
associated with obesity, insulin resistance, and type 2 
diabetes mellitus in Asian populations (34). Also, in a 
family-based study of the Chinese Han population, two 
SNPs of the ADIPOQ gene are associated with PCOS (30). 
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Generally, adiponectin is related to metabolic syndrome 
(insulin resistance, obesity, and dyslipidemia) in PCOS 
(42), which reflects the role of obesity in the mediation 
of adiponectin in PCOS. Because the genetic variants of 
the ADIPOQ gene in different racial populations were 
associated with PCOS (Table 1), this gene may be a risk 
factor for obesity and insulin resistance of PCOS.
FTO
Fat mass and obesity-associated (FTO) gene is a 
large gene that encodes 2-oxoglutarate-dependent 
nucleic acid demethylase and is mainly expressed in 
hypothalamic nuclei regulating feed intake. FTO has 
also been shown in other tissues such as liver, pancreas, 
muscles, and adipose tissue (43). Generally, the FTO 
 
  Figure 1. Causes of obesity and its adverse effects are expressed. Obesity mainly can occur due to genetic background and inappropriate lifestyle. 
Effect of abdominal obesity in exacerbating complications of PCOS is more than peripheral obesity. Abdominal obesity by alteration of metabolic 
clearance of androgens, increased levels of inflammatory mediators, and elevated beta cells mass in the pancreas is involved in hyperandrogenism, 
insulin resistance, and inflammation, respectively. The relationship between inflammation and hyperandrogenism is reciprocal, and androgens 
can create inflammation state
Table1. Candidate genes involved in etiology of polycystic ovary syndrome related to obesity and dyslipidemia
ADIPOQ: Adiponectin; FTO: Fat mass, and obesity-associated; MC4R: Melanocortin 4 receptor; SREBP-2: Sterol Regulatory Element Binding 
Protein-2; LXRa: Liver X Receptor a; ND: No data
Gene Genetic marker(s) Type of study Physiologic function Studied population Type of 
polymorphism 
References 
ADIPOQ T45G 
G276T 
Meta-analysis Glucose regulation and 
fatty acid oxidation 
Different 
population 
G276T (29) 
ADIPOQ rs2241766 
rs1501299 
Family-based 
analysis 
Glucose regulation and 
fatty acid oxidation 
Chinese Han rs1501299 (30) 
ADIPOQ SNPs at position −11377 of 
the ADIPOQ gene 
Case-control Glucose regulation and 
fatty acid oxidation 
Japanese ND (31) 
ADIPOQ 45T/G 
276G/T 
Meta-analysis Glucose regulation and 
fatty acid oxidation 
Different 
population 
45T/G 
276G/T 
(32) 
ADIPOQ C45G15G(T/G) 
C276(G/T) 
Case-control Glucose regulation and 
fatty acid oxidation 
Chinese Han +45G15G(T/G) 
+276(G/T) 
(33) 
ADIPOQ +45G15G(T/G) 
+276(G/T) 
Case-control Glucose regulation and 
fatty acid oxidation 
Korean +276(G/T) (34) 
FTO rs9939609 Case-control Energy homeostasis 
regulation 
British/Irish rs9939609 (35) 
FTO Five SNPs Family-based and 
case-control 
Energy homeostasis 
regulation 
White American rs1421085 (36) 
FTO rs9939609 Case-control Energy homeostasis 
regulation 
Australian rs9939609 (37) 
FTO rs1421085 
rs17817449 
rs8050136 
Case-control Energy homeostasis 
regulation 
Korean rs1421085 
rs17817449 
rs8050136 
(38) 
MC4R rs17782313 (T/C) Case-control Regulator of melanocortin 
neuronal pathways 
Chinese rs17782313 (39) 
MC4R rs12970134 Case-control Regulator of melanocortin 
neuronal pathways 
Czech rs12970134 (40) 
ADIPOQ rs2241766 Case-control Metabolic features of PCOS Iranian rs2241766 “TT” (41) 
SREBP-2 LXRa rs2228314 
rs11039155 
Case-control Lipid metabolism Chinese Han rs2228314 G to C 
rs11039155 G to A 
(28) 
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gene is associated with type 2 diabetes mellitus and 
obesity (38). In studies evaluating the association of 
FTO and PCOS, FTO was mainly associated with BMI 
and anthropometric parameters in women of various 
races with PCOS (37-39, 44) (Table 1). Increasing 
evidence suggests the association of variants of FTO 
with hyperandrogenemia in PCOS patients (37, 38). The 
relationship between FTO variants and impaired glucose 
tolerance, insulin resistance, and hyperandrogenism, 
that are prominent features of PCOS, are mediated via 
obesity and BMI (38). So, FTO can be a main genetic 
factor in predisposing to PCOS, primarily via an effective 
role in obesity and BMI, and secondarily with influencing 
the metabolic parameters and hyperandrogenemia.
MC4R
Melanocortin-4 receptor (MC4R) gene encodes 
the G-protein coupled receptor that is dominantly 
expressed in the brain and mediates the signaling 
pathway of melanocortin (45). MC4R has an important 
role in energy homeostasis and appetite and is the main 
genetic cause of obesity in humans (45, 46) and animals 
(47-49). Due to the critical role of MC4R in obesity 
pathology, the association between different SNPs of the 
MC4R gene and BMI and obesity in PCOS patients were 
demonstrated (36, 39, 40). According to the evidence, 
the MC4R gene via a causal effect on obesity contributes 
to PCOS etiology. The same evidence has been shown in 
PCOS animal models, too (50).
SREBP-2 and LXR
Given that insulin resistance disrupts lipid 
metabolism and serum lipid parameters, central 
transcription factors in metabolic pathways appear to 
be likely candidates for PCOS abnormalities (28). The 
central transcription factors of lipid metabolism, are 
liver X receptor (NR1H3, LXRa), and sterol regulatory 
element binding protein-2 (SREBP-2) (51-53). These 
two transcription factors regulate the expression of 
effective genes on lipoprotein metabolism, cholesterol 
homeostasis, and lipogenesis. LXRα transcription factor 
also plays a key action in insulin secretion of pancreatic 
Table 2. Candidate genes involved in etiology of polycystic ovary syndrome related to cell proliferation and signaling and chronic inflammation
DENND1A: DENN domain containing 1A; AQP8: Aquaporin 8; YAP1: yeast associated protein 1; TNF: Tumor necrosis factor; TGF-β1: transforming 
growth factor β1; TNFRSF1B: TNF receptor 2
Gene Genetic marker(s) Type of study Physiologic function Studied population Type of polymorphism Reference 
DENND1A rs2479106 Case control Clathrin-mediated endocytosis Caucasian rs2479106 G (61) 
DENND1A rs10818854 
rs2479106 
rs10986105 
Meta-analysis Clathrin-mediated endocytosis Asian and 
European 
rs10818854 
rs10986105 
(62) 
DENND1A rs2479106 
rs10818854 
Meta-analysis Clathrin-mediated endocytosis Chinese Han rs10818854 (63) 
DENND1A rs10818854 
rs2479106 
rs10986105 
Retrospective case-
control study 
Clathrin-mediated endocytosis Tunisian 0818854 
rs10986105 
(64) 
AQP8 rs7198838 
rs1076973 
rs1076974 
rs2287797 
rs2287798 
rs2287796 
case control Water channel protein Chinese Han rs2287798 (65) 
YAP1  rs11225138 
rs11225161 
rs1122516 
Replication study Transcriptional regulator Chinese Han rs11225161 (A/G) (66) 
TNF rs1799964 
rs1799724 
Family association Pro-inflammatory cytokine Chinese Han rs1799964 (67) 
TGF-β1 rs4803457C/T 
rs11466313 
deletion/AGG 
rs2217130C/T 
rs1800469C/T 
rs1800470C/T 
GWAS Low-grade chronic 
inflammation 
Chinese Han rs4803457C/T (68) 
TNFα 
IL-6 
IL-10 
−308 G/A 
−174 G/C 
−1082 G/A 
case-control Inflammatory cytokines Turkish IL-6 promoter region 
polymorphism 
(60) 
TNFRSF1B M196R (676 T→G) variant in exon 6 GWAS TNF signaling Spanish 
Italian 
M196R (676 T→G) (69) 
IL-6 -174 G/C Case- control Inflammatory cytokine Indian −174 G/C SNP (70) 
TNFα 
IL-6 
(−308 G/A), 
(−174 G/C) 
meta-analysis Chronic low-grade 
inflammation 
Different 
populations 
No association (71) 
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beta cells (53). The SREBP-2, which is encoded by a 
single gene on human chromosome 22, also plays an 
important role in maintaining lipid homeostasis (54). 
In a case-control study on Chinese Han women, variants 
of these two transcription factors were associated with 
PCOS (28). Although more research is needed to prove 
this association. 
Chronic inflammation-related genes in etiology of 
polycystic ovary syndrome
Inflammation can be the key marker of endothelial 
dysfunction, atherosclerosis and cardiovascular 
diseases, and also metabolic disruptions of PCOS. It 
seems inflammatory reactions are more often secondary 
pathways in PCOS etiology and are affected by obesity and 
hyperglycemia. Glucose-induced nuclear factor-κB (NF-
κB) activation from mononuclear cells eventually leads to 
beta cell dysfunction and insulin secretion irregularities 
in PCOS (55). Adipokines derived adipocytes contribute 
to inflammation and insulin resistance development. For 
instance, decreased adiponectin and increased TNFα and 
IL-6 are contributed to insulin resistance development.
PCOS is an inflammatory state, and chronic 
inflammatory-related genes may be effective in 
the incidence of PCOS through mediating role in 
hyperandrogenism, obesity, insulin resistance, and 
anovulation (56). Chronic inflammation is involved in the 
development of PCOS. Dietary glucose-induced oxidative 
stress by the particular molecular signaling pathway 
leads to increased production of pro-inflammatory 
cytokines from mononuclear cells (MNC). 
Hyperandrogenism may be the progenitor of low-grade 
chronic inflammation in PCOS and via increase of MNC 
sensitivity, stimulates glucose-induced inflammation 
(57). On the other hand, the pro-inflammatory cytokines, 
TNFα, can elevate the production of androgens with 
upregulation of steroidogenic enzymes and stimulation 
of proliferation of theca cells. Also, TNFα is a mediator 
of insulin resistance, thus it is  likely dietary-induced 
inflammation, is the base of insulin resistance in PCOS 
(57). Exposure of androgen excess prone the adipocytes 
to hypertrophy and hypertrophic adipocytes were 
observed in PCOS women. Hypertrophic adipocytes 
were more predisposed to inflammation (58). Adipose 
tissue adipocytes in an autocrine/paracrine manner by 
secretion of products, some of which are inflammation 
factors, contributed to low-grade inflammation related 
to PCOS (13). The low-grade chronic inflammation 
in PCOS may be related to hyperandrogenism and 
hypertrophic adipocyte (58).
The correlation between the incidence of PCOS 
and chronic inflammation has increased attention 
to the inflammatory factors coding genes and their 
association with PCOS (59). The imbalance between 
pro-inflammatory and anti-inflammatory cytokines 
and cytokine genes polymorphisms may be involved in 
etiology of PCOS (60). Therefore, inflammatory reactions 
act as mediators and contribute to the development and 
aggravation of metabolic properties of PCOS (Figure 2). 
The genes related to chronic inflammation are presented 
in Table 2.
TGF-β1
The beta-transforming growth factor-β (TGF-β1) is 
a component of multifunctional cytokines family and 
mediates wound healing, tissue fibrosis, and embryonic 
development (68). In recent years, pathogenic immunity 
factors have been widely considered in PCOS, which 
shows PCOS is a low-grade chronic inflammatory 
condition (68). PCOS patients showed higher levels of 
lymphocytes, monocytes, and eosinophils, plus CRPs, 
TNFα, and IL-6 in serum, all of which are peripheral 
inflammatory factors (72, 73). Moreover, PCOS ovaries 
showed chronic inflammation and higher numbers of 
inflammatory cells compared to normal conditions. 
Cytokines seem to be important for folliculogenesis and 
 
Figure 2. Pathophysiological pathways contribute to low-grade inflammation in polycystic ovary syndrome (PCOS). Glucose-induced oxidative 
stress by production of inflammatory cytokines leads to insulin resistance. Cytokines via effects on theca cells eventually create hyperandrogenism. 
Macrophage derived mononuclear cells resulted in adipocytes hypertrophy and in turn by secretion of inflammatory cytokine create low-grade 
chronic inflammation
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ovulation and also participate in the process of follicular 
atresia and corpus luteum regression by activating 
immune cells (68, 74). Polymorphism of rs4803457C/T 
in TGFβ gene was associated with susceptibility to PCOS 
and was demonstrated as the main constituent of PCOS 
development in Chinese women (68).
TNFα 
It is reported that the TNFα cytokine is secreted by 
adipose tissue and plays an essential role in mediating 
insulin resistance and as a result of obesity (75). 
The TNFα pro-inflammatory cytokine is known as a 
mediator of insulin resistance in PCOS (57). Androgen 
excess promotes the release of TNFα from MNCs in vivo 
and in vitro (76). TNFα plays a cardinal role in oxidative 
stress and inflammation; in PCOS, production of TNFα 
is induced by hyperglycemia and hyperandrogenemia 
(77). Serine phosphorylation of Insulin receptor 
substrate 1 (IRS-1) seems to be a mechanism for insulin 
resistance by mediating TNFα (78). Overexpression of 
TNFα in peripheral tissues such as muscle and adipose, 
by reducing the tyrosine kinase activity in the insulin 
signaling pathway, is one of the mechanisms for insulin 
resistance development mediated by TNFα (78). Also, 
TNFα directly effects ovary and adrenal function (10) 
and then increases steroidogenesis in theca cells in vitro 
(79). Despite the finding that TNFα is the mediator of 
insulin resistance, a significant association of TNFα gene 
with PCOS was not observed.
TNFRS1β
The TNF receptor superfamily 1β is a member of 
TNFα receptors that are said to localize on the surface 
of all normal and tumor cells (80). Type 2 TNF receptor 
mediates most of the metabolic effects of TNFα. Its serum 
levels increase in obese subjects correlating with insulin 
resistance indices (81). The M196R variant in exon 6 of 
the TNF receptor superfamily 1β (TNFRS1β) gene was 
associated with hyperandrogenism and PCOS in the 
study of hyperandrogenic and PCOS Spanish women 
(82). It has also been suggested that TNFα cytokines 
were able to induce proliferation of theca internal cells 
in porcine ovaries (80).
IL-6
IL-6 is a pleiotropic cytokine and is secreted by 
numerous cells including lymphocytes, monocytes, 
and endothelial cells. Interleukin-6 is involved in 
reproductive physiologic processes, such as regulating 
of ovarian steroid production, follicular maturation, 
fertilization, implantation, and modulating of ovarian 
development and functions (70). Concentrations of the 
IL-6 and CRP increase in obese women, but not in PCOS 
patients (14). It is shown that the polymorphism of the 
promoter region of the IL-6 gene could be associated 
with the occurrence of metabolic abnormalities in 
Turkish PCOS women (60). Also, IL-6 may have a 
direct effect on ovaries and adrenal cells (10). In vitro 
studies have shown that IL-6 induced the function of 
human adrenal cells, in turn, elevated steroidogenesis 
in adrenals (83). The results of an investigation of IL-6 
gene polymorphisms are very inconsistent (Table 2), 
which is possibly related to racial background, genetic 
variants, and epigenetic environmental factors among 
different populations (70).
DENND1A
Differentially expressed in normal and neoplastic 
(cell) domain containing 1A (DENND1A) is a member 
of connecdenn proteins family. These proteins have 
differential expression in normal and neoplastic 
domains of cells (84). The DENND1A gene encodes the 
connecdenn-1 protein, which has a clathrin-binding 
domain and facilitates receptor-mediated endocytosis 
and participates in endosomes trafficking (84, 85). 
Overexpression of variant 2 DENND1A, alternative 
splicing of DENND1A, in PCOS theca cells was observed, 
which can contribute to androgen overproduction in 
these cells (86). High expression of variant 2 DENND1A 
leads to over mRNA expression of cytochrome P450 
17A1 (CYP17A1) and hyperactivity of CYP11A1 and 
CYP17A1, which in turn increases the level of androgen 
production in theca cells (86). So, DENND1A can be a 
mediator for hyperandrogenism of PCOS, and maybe 
through this pathway connect to hyperandrogenism, 
the common loop of all hypotheses of PCOS. Previous 
studies reported DENND1A as a susceptibility locus 
in PCOS, but there are racial differences about this 
association (64). Even though the DENND1A locus in 
various GWAS among different populations is identified 
as a risk locus in PCOS and maybe a valuable gene in 
PCOS pathogenesis and diagnosis, it is not applicable to 
all populations.
Conclusion
To sum up, identifying the root cause of PCOS as a 
heterogeneous disorder is hard and at the same time, 
it provides the basis of many investigations. So far, 
the role of hyperandrogenism and its pre- and post-
pathways in PCOS development is better explained 
and confirmed; various backgrounds including genetic, 
environmental factors, and developmental origins can 
interfere in its creation. Hyperandrogenism can also 
be caused by insulin resistance. While the roles of 
hyperandrogenism and hyperinsulinemia are the major 
reasons for PCOS development, but abdominal obesity 
and low-grade inflammation can play a significant role 
through the mediation of some pathways leading to 
insulin resistance and hyperandrogenism. As foregoing, 
chronic inflammation and obesity are not necessarily 
primary factors, and sometimes their role exacerbates 
the syndrome or even themselves as a consequence of 
the syndrome. It seems that genes related to obesity 
pathology (FTO, ADIPOQ, and MC4R), in genomic 
research association, are related to metabolic aspects 
and BMI in PCOS patients. These findings suggest that 
obesity, especially abdominal phenotype, completes 
and exacerbates the phenotypic picture of PCOS. 
Inflammation also occurs, followed by obesity and has 
the same role in PCOS. It should be kept in mind that 
these hypotheses are better evaluated by clinical and 
experimental research such as animal models and 
therapeutic approaches. 
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